Drug Patents owned by Boehringer Ingelheim

1. List of Atrovent Hfa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8474447 BOEHRINGER INGELHEIM Inhaler device
Jan, 2030

(6 years from now)

Drugs and Companies using IPRATROPIUM BROMIDE ingredient

Market Authorisation Date: 27 November, 2004

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

2. List of Combivent Respimat drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7284474 BOEHRINGER INGELHEIM Piston-pumping system having o-ring seal properties
Aug, 2024

(1 year, 6 months from now)

US7896264 BOEHRINGER INGELHEIM Microstructured high pressure nozzle with built-in filter function
May, 2025

(2 years from now)

US7396341 BOEHRINGER INGELHEIM Blocking device for a locking stressing mechanism having a spring-actuated output drive device
Oct, 2026

(3 years from now)

US9027967 BOEHRINGER INGELHEIM Device for clamping a fluidic component
Mar, 2027

(4 years from now)

US7837235 BOEHRINGER INGELHEIM Device for clamping a fluidic component
Mar, 2028

(5 years from now)

US8733341 BOEHRINGER INGELHEIM Atomizer and method of atomizing fluid with a nozzle rinsing mechanism
Oct, 2030

(7 years from now)

Drugs and Companies using ALBUTEROL SULFATE; IPRATROPIUM BROMIDE ingredient

Market Authorisation Date: 07 October, 2011

Treatment: NA

Dosage: SPRAY, METERED;INHALATION

More Information on Dosage

3. List of Gilotrif drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE43431 BOEHRINGER INGELHEIM Quinazoline derivatives and pharmaceutical compositions containing them
Jan, 2026

(2 years from now)

US8426586 BOEHRINGER INGELHEIM Process for preparing amino crotonyl compounds
Oct, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE43431

(Pediatric)

BOEHRINGER INGELHEIM Quinazoline derivatives and pharmaceutical compositions containing them
Jul, 2026

(3 years from now)

US9539258 BOEHRINGER INGELHEIM Quinazoline derivatives for the treatment of cancer diseases
Nov, 2026

(3 years from now)

US9539258

(Pediatric)

BOEHRINGER INGELHEIM Quinazoline derivatives for the treatment of cancer diseases
May, 2027

(4 years from now)

US8545884 BOEHRINGER INGELHEIM Solid pharmaceutical formulations comprising BIBW 2992
Dec, 2029

(6 years from now)

US8426586

(Pediatric)

BOEHRINGER INGELHEIM Process for preparing amino crotonyl compounds
Apr, 2030

(7 years from now)

US8545884

(Pediatric)

BOEHRINGER INGELHEIM Solid pharmaceutical formulations comprising BIBW 2992
Jun, 2030

(7 years from now)

US10004743 BOEHRINGER INGELHEIM Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
Jul, 2030

(7 years from now)

US10004743

(Pediatric)

BOEHRINGER INGELHEIM Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
Jan, 2031

(7 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jan 12, 2025
M Apr 7, 2025
Pediatric Exclusivity (PED) Oct 15, 2023

Drugs and Companies using AFATINIB DIMALEATE ingredient

Market Authorisation Date: 12 July, 2013

Treatment: Treatment of patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy

Dosage: TABLET;ORAL

How can I launch a generic of GILOTRIF before it's patent expiration?
More Information on Dosage

4. List of Glyxambi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7407955 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
May, 2025

(2 years from now)

US7713938 BOEHRINGER INGELHEIM Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Apr, 2027

(4 years from now)

US7579449 BOEHRINGER INGELHEIM Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Aug, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8119648 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(6 months from now)

US8178541 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(6 months from now)

US8883805 BOEHRINGER INGELHEIM Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
Nov, 2025

(2 years from now)

US11033552 BOEHRINGER INGELHEIM DPP IV inhibitor formulations
May, 2027

(4 years from now)

US9173859 BOEHRINGER INGELHEIM Uses of DPP IV inhibitors
May, 2027

(4 years from now)

US8673927 BOEHRINGER INGELHEIM Uses of DPP-IV inhibitors
May, 2027

(4 years from now)

US8551957 BOEHRINGER INGELHEIM Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate
Oct, 2029

(6 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(11 years from now)

US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(11 years from now)

US9949998 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Jun, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
M Jul 3, 2022

Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient

Market Authorisation Date: 30 January, 2015

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin; Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin (with or without insulin or a sulfonylurea); Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin (with or without metformin); Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin and metformin; Method of treating type 2 diabetes mellitus in a patient with renal impairment (30 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin

Dosage: TABLET;ORAL

How can I launch a generic of GLYXAMBI before it's patent expiration?
More Information on Dosage

5. List of Jardiance drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7713938 BOEHRINGER INGELHEIM Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Apr, 2027

(4 years from now)

US7579449 BOEHRINGER INGELHEIM Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Aug, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8551957 BOEHRINGER INGELHEIM Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate
Oct, 2029

(6 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(11 years from now)

US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(11 years from now)

US9949997 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
May, 2034

(11 years from now)

US9949998 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Jun, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Aug 18, 2024
M Feb 24, 2025

Drugs and Companies using EMPAGLIFLOZIN ingredient

Market Authorisation Date: 01 August, 2014

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin; Method of treating type 2 diabetes mellitus in a patient with renal impairment (30 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of reducing the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and cardiovascular disease by once daily administration of 10 mg or 25 mg of empagliflozin; Method for reducing the risk of cardiovascular death and hospitalization for heart failure in adults with type 2 diabetes mellitus and heart failure by once daily administration of empagliflozin; Method for reducing the risk of cardiovascular death plus hospitalization for heart failure in adults with type 2 diabetes mellitus, heart failure and reduced ejection fraction by once daily administration of empagliflozin

Dosage: TABLET;ORAL

How can I launch a generic of JARDIANCE before it's patent expiration?
More Information on Dosage

6. List of Jentadueto drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7407955 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
May, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8178541 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(6 months from now)

US8119648 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(6 months from now)

US8883805 BOEHRINGER INGELHEIM Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
Nov, 2025

(2 years from now)

US8673927 BOEHRINGER INGELHEIM Uses of DPP-IV inhibitors
May, 2027

(4 years from now)

US10022379 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Apr, 2029

(6 years from now)

US9415016 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Apr, 2029

(6 years from now)

US10973827 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Apr, 2029

(6 years from now)

US9155705 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
May, 2030

(7 years from now)

US8846695 BOEHRINGER INGELHEIM Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor
Jun, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
M Jul 3, 2022

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 30 January, 2012

Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin and/or a sulfonylurea; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor; Method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin; Use of a pharmaceutical composition comprising linagliptin, metformin and a basic amino acid to treat type 2 diabetes mellitus

Dosage: TABLET;ORAL

How can I launch a generic of JENTADUETO before it's patent expiration?
More Information on Dosage

7. List of Jentadueto Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7407955 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
May, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8119648 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(6 months from now)

US8178541 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(6 months from now)

US8883805 BOEHRINGER INGELHEIM Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
Nov, 2025

(2 years from now)

US8673927 BOEHRINGER INGELHEIM Uses of DPP-IV inhibitors
May, 2027

(4 years from now)

US9173859 BOEHRINGER INGELHEIM Uses of DPP IV inhibitors
May, 2027

(4 years from now)

US10022379 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Apr, 2029

(6 years from now)

US9415016 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Apr, 2029

(6 years from now)

US9155705 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
May, 2030

(7 years from now)

US9555001 BOEHRINGER INGELHEIM Pharmaceutical composition and uses thereof
Mar, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
M Jul 3, 2022

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 27 May, 2016

Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin and, optionally, a sulfonylurea; Method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin; Use of a pharmaceutical composition comprising linagliptin, metformin and a basic amino acid to treat type 2 diabetes mellitus; Method of treating type 2 diabetes in patients with insufficient glycemic control despite therapy with one or more conventional antihyperglycemic agents by administering linagliptin in combination with metformin; Method of treating type 2 diabetes in patients who have not been previously treated with an antihyperglycemic agent by administering linagliptin in combination with metformin

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of JENTADUETO XR before it's patent expiration?
More Information on Dosage

8. List of Micardis drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8003679 BOEHRINGER INGELHEIM Use of inhibitors of the renin-angiotensin system
Oct, 2022

(3 months ago)

Drugs and Companies using TELMISARTAN ingredient

Market Authorisation Date: 10 November, 1998

Treatment: Treatment or prevention of stroke

Dosage: TABLET;ORAL

How can I launch a generic of MICARDIS before it's patent expiration?
More Information on Dosage

9. List of Mirapex Er drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7695734 BOEHRINGER INGELHEIM Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
Apr, 2028

(5 years from now)

US8679533 BOEHRINGER INGELHEIM Pramipexole once-daily dosage form
Sep, 2029

(6 years from now)

Drugs and Companies using PRAMIPEXOLE DIHYDROCHLORIDE ingredient

Market Authorisation Date: 19 February, 2010

Treatment: Treatment of parkinson's disease

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of MIRAPEX ER before it's patent expiration?
More Information on Dosage

10. List of Ofev drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7119093 BOEHRINGER INGELHEIM 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition
Feb, 2024

(1 year, 17 days from now)

US6762180 BOEHRINGER INGELHEIM Substituted indolines which inhibit receptor tyrosine kinases
Oct, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10154990 BOEHRINGER INGELHEIM Medicaments for the treatment or prevention of fibrotic diseases
Dec, 2025

(2 years from now)

US10105323 BOEHRINGER INGELHEIM Pharmaceutical dosage form for immediate release of an indolinone derivative
Jun, 2029

(6 years from now)

US9907756 BOEHRINGER INGELHEIM Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
Jun, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Mar 9, 2023
Orphan Drug Exclusivity (ODE) Sep 6, 2026

Drugs and Companies using NINTEDANIB ESYLATE ingredient

Market Authorisation Date: 15 October, 2014

Treatment: Use of nintedanib for slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (ssc-ild)

Dosage: CAPSULE;ORAL

How can I launch a generic of OFEV before it's patent expiration?
More Information on Dosage

11. List of Pradaxa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7932273 BOEHRINGER INGELHEIM 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament
Sep, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6087380

(Pediatric)

BOEHRINGER INGELHEIM Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
Jun, 2022

(7 months ago)

US9925174 BOEHRINGER INGELHEIM Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof
Jun, 2023

(4 months from now)

US9925174

(Pediatric)

BOEHRINGER INGELHEIM Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof
Dec, 2023

(10 months from now)

US7932273

(Pediatric)

BOEHRINGER INGELHEIM 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament
Mar, 2026

(3 years from now)

US7866474 BOEHRINGER INGELHEIM Film container
Aug, 2027

(4 years from now)

US7866474

(Pediatric)

BOEHRINGER INGELHEIM Film container
Mar, 2028

(5 years from now)

US9034822 BOEHRINGER INGELHEIM Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds
Jan, 2031

(7 years from now)

US9034822

(Pediatric)

BOEHRINGER INGELHEIM Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds
Jul, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Jun 21, 2024
Pediatric Exclusivity (PED) Dec 21, 2024

Drugs and Companies using DABIGATRAN ETEXILATE MESYLATE ingredient

Market Authorisation Date: 19 October, 2010

Treatment: Method of reversing the anticoagulant effect of dabigatran using idarucizumab

Dosage: CAPSULE;ORAL

How can I launch a generic of PRADAXA before it's patent expiration?
More Information on Dosage

12. List of Spiriva drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7070800 BOEHRINGER INGELHEIM Inhalable powder containing tiotropium
Jan, 2022

(1 year, 12 days ago)

US7309707

(Pediatric)

BOEHRINGER INGELHEIM Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
Mar, 2022

(10 months ago)

US7642268

(Pediatric)

BOEHRINGER INGELHEIM Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
Mar, 2022

(10 months ago)

US6908928

(Pediatric)

BOEHRINGER INGELHEIM Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
Mar, 2022

(10 months ago)

US6777423

(Pediatric)

BOEHRINGER INGELHEIM Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
Mar, 2022

(10 months ago)

USRE38912

(Pediatric)

BOEHRINGER INGELHEIM Process for preparing powder formulations
Apr, 2022

(9 months ago)

US7070800

(Pediatric)

BOEHRINGER INGELHEIM Inhalable powder containing tiotropium
Jul, 2022

(6 months ago)

US8022082 BOEHRINGER INGELHEIM Method for the administration of an anticholinergic by inhalation
Jan, 2026

(2 years from now)

US8022082

(Pediatric)

BOEHRINGER INGELHEIM Method for the administration of an anticholinergic by inhalation
Jul, 2026

(3 years from now)

US7694676 BOEHRINGER INGELHEIM Dry powder inhaler
Mar, 2027

(4 years from now)

US7694676

(Pediatric)

BOEHRINGER INGELHEIM Dry powder inhaler
Sep, 2027

(4 years from now)

US9010323 BOEHRINGER INGELHEIM Inhaler and sieve for an inhaler
Apr, 2030

(7 years from now)

Drugs and Companies using TIOTROPIUM BROMIDE ingredient

Market Authorisation Date: 30 January, 2004

Treatment: For the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema; Administration of an inhalable powder comprising tiotropium via device

Dosage: POWDER;INHALATION

How can I launch a generic of SPIRIVA before it's patent expiration?
More Information on Dosage

13. List of Spiriva Respimat drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7988001

(Pediatric)

BOEHRINGER INGELHEIM Container provided with a pressure equalization opening
Feb, 2022

(11 months ago)

US7284474 BOEHRINGER INGELHEIM Piston-pumping system having o-ring seal properties
Aug, 2024

(1 year, 6 months from now)

US7284474

(Pediatric)

BOEHRINGER INGELHEIM Piston-pumping system having o-ring seal properties
Feb, 2025

(2 years from now)

US7896264 BOEHRINGER INGELHEIM Microstructured high pressure nozzle with built-in filter function
May, 2025

(2 years from now)

US7896264

(Pediatric)

BOEHRINGER INGELHEIM Microstructured high pressure nozzle with built-in filter function
Nov, 2025

(2 years from now)

US7396341 BOEHRINGER INGELHEIM Blocking device for a locking stressing mechanism having a spring-actuated output drive device
Oct, 2026

(3 years from now)

US9027967 BOEHRINGER INGELHEIM Device for clamping a fluidic component
Mar, 2027

(4 years from now)

US7396341

(Pediatric)

BOEHRINGER INGELHEIM Blocking device for a locking stressing mechanism having a spring-actuated output drive device
Apr, 2027

(4 years from now)

US9027967

(Pediatric)

BOEHRINGER INGELHEIM Device for clamping a fluidic component
Oct, 2027

(4 years from now)

US7837235 BOEHRINGER INGELHEIM Device for clamping a fluidic component
Mar, 2028

(5 years from now)

US7837235

(Pediatric)

BOEHRINGER INGELHEIM Device for clamping a fluidic component
Sep, 2028

(5 years from now)

US8733341 BOEHRINGER INGELHEIM Atomizer and method of atomizing fluid with a nozzle rinsing mechanism
Oct, 2030

(7 years from now)

US8733341

(Pediatric)

BOEHRINGER INGELHEIM Atomizer and method of atomizing fluid with a nozzle rinsing mechanism
Apr, 2031

(8 years from now)

Drugs and Companies using TIOTROPIUM BROMIDE ingredient

Market Authorisation Date: 24 September, 2014

Treatment: NA

Dosage: SPRAY, METERED;INHALATION

More Information on Dosage

14. List of Stiolto Respimat drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7491719 BOEHRINGER INGELHEIM Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments
Nov, 2023

(9 months from now)

US7056916 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease
Dec, 2023

(10 months from now)

US7220742 BOEHRINGER INGELHEIM Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
May, 2025

(2 years from now)

US7727984 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease
Jan, 2027

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8044046 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease
Nov, 2023

(9 months from now)

US7786111 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease
Nov, 2023

(9 months from now)

US7284474 BOEHRINGER INGELHEIM Piston-pumping system having o-ring seal properties
Aug, 2024

(1 year, 6 months from now)

US7284474

(Pediatric)

BOEHRINGER INGELHEIM Piston-pumping system having o-ring seal properties
Feb, 2025

(2 years from now)

US8034809 BOEHRINGER INGELHEIM Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
May, 2025

(2 years from now)

US7896264 BOEHRINGER INGELHEIM Microstructured high pressure nozzle with built-in filter function
May, 2025

(2 years from now)

US7396341 BOEHRINGER INGELHEIM Blocking device for a locking stressing mechanism having a spring-actuated output drive device
Oct, 2026

(3 years from now)

US9027967 BOEHRINGER INGELHEIM Device for clamping a fluidic component
Mar, 2027

(4 years from now)

US7396341

(Pediatric)

BOEHRINGER INGELHEIM Blocking device for a locking stressing mechanism having a spring-actuated output drive device
Apr, 2027

(4 years from now)

US7837235 BOEHRINGER INGELHEIM Device for clamping a fluidic component
Mar, 2028

(5 years from now)

US7837235

(Pediatric)

BOEHRINGER INGELHEIM Device for clamping a fluidic component
Sep, 2028

(5 years from now)

US8733341 BOEHRINGER INGELHEIM Atomizer and method of atomizing fluid with a nozzle rinsing mechanism
Oct, 2030

(7 years from now)

Drugs and Companies using OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE ingredient

Market Authorisation Date: 21 May, 2015

Treatment: Treatment of copd; Treatment of respiratory complaints

Dosage: SPRAY, METERED;INHALATION

More Information on Dosage

15. List of Striverdi Respimat drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7491719 BOEHRINGER INGELHEIM Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments
Nov, 2023

(9 months from now)

US7056916 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease
Dec, 2023

(10 months from now)

US7220742 BOEHRINGER INGELHEIM Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
May, 2025

(2 years from now)

US7727984 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease
Jan, 2027

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8044046 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease
Nov, 2023

(9 months from now)

US7786111 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease
Nov, 2023

(9 months from now)

US7284474 BOEHRINGER INGELHEIM Piston-pumping system having o-ring seal properties
Aug, 2024

(1 year, 6 months from now)

US8034809 BOEHRINGER INGELHEIM Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
May, 2025

(2 years from now)

US7896264 BOEHRINGER INGELHEIM Microstructured high pressure nozzle with built-in filter function
May, 2025

(2 years from now)

US7396341 BOEHRINGER INGELHEIM Blocking device for a locking stressing mechanism having a spring-actuated output drive device
Oct, 2026

(3 years from now)

US9027967 BOEHRINGER INGELHEIM Device for clamping a fluidic component
Mar, 2027

(4 years from now)

US7837235 BOEHRINGER INGELHEIM Device for clamping a fluidic component
Mar, 2028

(5 years from now)

US8733341 BOEHRINGER INGELHEIM Atomizer and method of atomizing fluid with a nozzle rinsing mechanism
Oct, 2030

(7 years from now)

Drugs and Companies using OLODATEROL HYDROCHLORIDE ingredient

Market Authorisation Date: 31 July, 2014

Treatment: Treatment of chronic obstructive pulmonary disease (copd), chronic bronchitis or emphysema

Dosage: SPRAY, METERED;INHALATION

More Information on Dosage

16. List of Synjardy drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7713938 BOEHRINGER INGELHEIM Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Apr, 2027

(4 years from now)

US7579449 BOEHRINGER INGELHEIM Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Aug, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10610489 BOEHRINGER INGELHEIM Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
Sep, 2030

(7 years from now)

US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(11 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(11 years from now)

Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 26 August, 2015

Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of treating type 2 diabetes mellitus in a patent with renal impairment (egfr<60 ml/min/1.73 m2) by initiation of empagliflozin and metformin hcl if egfr>=45 ml/min/1.73 m2 and discontinuation if egfr<30 ml/min/1.73 m2

Dosage: TABLET;ORAL

How can I launch a generic of SYNJARDY before it's patent expiration?
More Information on Dosage

17. List of Synjardy Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7713938 BOEHRINGER INGELHEIM Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Apr, 2027

(4 years from now)

US7579449 BOEHRINGER INGELHEIM Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Aug, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10596120 BOEHRINGER INGELHEIM Pharmaceutical compositions
Mar, 2032

(9 years from now)

US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(11 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(11 years from now)

US9949998 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Jun, 2034

(11 years from now)

Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 09 December, 2016

Treatment: Treatment of a type 2 diabetes mellitus patient with insufficient glycemic control despite metformin therapy using a composition comprising an extended release core comprising metformin and an outer coating comprising empagliflozin; Treatment of a treatment-naïve patient with inadequately controlled type 2 diabetes using a composition comprising an extended release core comprising metformin and an outer coating comprising empagliflozin; Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of treating type 2 diabetes mellitus in a patent with renal impairment (egfr<60 ml/min/1.73 m2) by initiation of empagliflozin and metformin hcl if egfr>=45 ml/min/1.73 m2 and discontinuation if egfr<30 ml/min/1.73 m2

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of SYNJARDY XR before it's patent expiration?
More Information on Dosage

18. List of Tradjenta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7407955 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
May, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8178541 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(6 months from now)

US8119648 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(6 months from now)

US8883805 BOEHRINGER INGELHEIM Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
Nov, 2025

(2 years from now)

US8673927 BOEHRINGER INGELHEIM Uses of DPP-IV inhibitors
May, 2027

(4 years from now)

US11033552 BOEHRINGER INGELHEIM DPP IV inhibitor formulations
May, 2027

(4 years from now)

US10034877 BOEHRINGER INGELHEIM Treatment for diabetes in patients inappropriate for metformin therapy
Aug, 2029

(6 years from now)

US9486526 BOEHRINGER INGELHEIM Treatment for diabetes in patients inappropriate for metformin therapy
Aug, 2029

(6 years from now)

US8846695 BOEHRINGER INGELHEIM Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor
Jun, 2030

(7 years from now)

US8853156 BOEHRINGER INGELHEIM Treatment for diabetes in patients inappropriate for metformin therapy
Mar, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
M Jul 3, 2022

Drugs and Companies using LINAGLIPTIN ingredient

Market Authorisation Date: 02 May, 2011

Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with sulfonlyurea; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin and/or a sulfonylurea; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with pioglitazone; Method of treating type 2 diabetes mellitus by administering linagliptin in combination with insulin (with or without metformin and/or pioglitazone); Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor; Method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin; Treatment of type 2 diabetes mellitus in a patient with renal impairment and for whom metformin therapy is inappropriate by administering linagliptin without dose adjustment; Method of treating type 2 diabetes mellitus in patients with severe chronic renal impairment and who are ineligible for metformin therapy by administering linagliptin; Method of treating type 2 diabetes mellitus in patients with severe chronic renal impairment and for whom metformin therapy is inappropriate by administering linagliptin

Dosage: TABLET;ORAL

How can I launch a generic of TRADJENTA before it's patent expiration?
More Information on Dosage

19. List of Trijardy Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7407955 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
May, 2025

(2 years from now)

US7713938 BOEHRINGER INGELHEIM Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Apr, 2027

(4 years from now)

US7579449 BOEHRINGER INGELHEIM Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Aug, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8178541 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(6 months from now)

US8119648 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(6 months from now)

US8883805 BOEHRINGER INGELHEIM Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
Nov, 2025

(2 years from now)

US10022379 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Apr, 2029

(6 years from now)

US9415016 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Apr, 2029

(6 years from now)

US8551957 BOEHRINGER INGELHEIM Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate
Oct, 2029

(6 years from now)

US9155705 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
May, 2030

(7 years from now)

US10406172 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Jun, 2030

(7 years from now)

US10596120 BOEHRINGER INGELHEIM Pharmaceutical compositions
Mar, 2032

(9 years from now)

US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(11 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(11 years from now)

US9949998 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Jun, 2034

(11 years from now)

Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 27 January, 2020

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin and metformin; Method of treating type 2 diabetes using a pharmaceutical composition comprising linagliptin, metformin, empagliflozin and a basic amino acid; Method of treating type 2 diabetes mellitus using a pharmaceutical composition comprising empagliflozin, linagliptin and metformin; Method of treating a type 2 diabetes mellitus patient with insufficient glycemic control despite therapy with metformin using a pharmaceutical composition comprising empagliflozin, linagliptin and metformin; Treatment of a treatment-naive patient with inadequately controlled type 2 diabetes using a composition comprising an extended release core comprisingmetformin and an outer coating comprising empagliflozin and linagliptin; Treatment of a type 2 diabetes mellitus patient with insufficient glycemic control despite metformin therapy using a composition comprising an extended release core comprising metformin and an outer coating comprising empagliflozin and linagliptin; Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin in combination with linagliptin and metformin; Method of treating type 2 diabetes mellitus in a patient with renal impairment (egfr<60 ml/min/1.73 m2) by initiation of empagliflozin, linagliptin and metformin hcl if egfr>=45 ml/min/1.73 m2 and discontinuation if egfr <30 ml/min/1.73 m2

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of TRIJARDY XR before it's patent expiration?
More Information on Dosage

20. List of Viramune Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8460704 BOEHRINGER INGELHEIM Extended release formulation of nevirapine
Mar, 2029

(6 years from now)

Drugs and Companies using NEVIRAPINE ingredient

Market Authorisation Date: 25 March, 2011

Treatment: Treatment of hiv-1 by once daily administration

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of VIRAMUNE XR before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in